Neogen Corporation Business Acquisition, Pro Forma Revenue
Neogen Corporation (NEOG) reported Business Acquisition, Pro Forma Revenue of $38.00 million for the 12-month period ending 2022-05-31, per its 10-K filed 2022-07-27.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2022-07-27
- Neogen Corporation business acquisition, pro forma revenue for fiscal 2022 was $38.00M, a 40.74% increase from fiscal 2021.
- Neogen Corporation business acquisition, pro forma revenue for fiscal 2021 was $27.00M, a 342.62% increase from fiscal 2020.
- Neogen Corporation business acquisition, pro forma revenue for fiscal 2020 was $6.10M.
| Period end | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|
| 2022-05-31 | $38.00M 10-K · filed 2022-07-27 |
| 2021-05-31 | $27.00M 10-K · filed 2022-07-27 |
| 2020-05-31 | $6.10M 10-K · filed 2022-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |